Protagonist Therapeutics (PTGX) EBT Margin (2017 - 2026)

Protagonist Therapeutics has disclosed EBT Margin across 10 years of filings, most recently posting 4.05% for Q1 2026.

• EBT Margin for Q1 2026 came in at 4.05%, up 4520.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 155.78% (down 4582.0% YoY), and the FY2025 annual result was 281.01%, down 28102.0% from the prior year.
• EBT Margin came in at 4.05% for Q1 2026 at Protagonist Therapeutics, up from 587.84% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 180342.11% in Q4 2022 to a low of 4768.22% in Q2 2022.
• The 5-year median for EBT Margin is 88.31% (2024), against an average of 13246.63%.
• Across the five-year window, EBT Margin surged 18077041 bps in 2022 and plunged 18006876 bps in 2023, its largest moves.
• Protagonist Therapeutics' EBT Margin stood at 180342.11% in 2022, then sank by 100 bps to 273.35% in 2023, then tumbled by 132 bps to 88.31% in 2024, then tumbled by 566 bps to 587.84% in 2025, then jumped by 101 bps to 4.05% in 2026.
• The last three EBT Margin figures came in at 4.05% (Q1 2026), 587.84% (Q4 2025), and 834.87% (Q3 2025), per Business Quant data.